Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
Short/dysfunctional telomeres are at the origin of idiopathic pulmonary fibrosis (IPF) in patients mutant for telomere maintenance genes. However, it remains unknown whether physiological aging leads to short telomeres in the lung, thus leading to IPF with aging. Here, we find that physiological aging in wild-type mice leads to telomere shortening and a reduced proliferative potential of alveolar type II cells and club cells, increased cellular senescence and DNA damage, increased fibroblast activation and collagen deposits, and impaired lung biophysics, suggestive of a fibrosis-like pathology. Treatment of both wild-type and telomerase-deficient mice with telomerase gene therapy prevented the onset of lung profibrotic pathologies. These findings suggest that short telomeres associated with physiological aging are at the origin of IPF and that a potential treatment for IPF based on telomerase activation would be of interest not only for patients with telomerase mutations but also for sporadic cases of IPF associated with physiological aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Telomerase deficiency and natural aging in the mouse lung leads to telomere shortening and reduction in the number of ATII and club cells. (A and B) Generation of Tert+/+ and G3 Tert−/− mice and scheme of lung tissue harvesting. (A) Heterozygous Tert+/− mice were crossed to obtain Tert+/+ and G1 Tert−/− mice, and successive crosses between G1 Tert−/− and then G2 Tert−/− mice were made to generate G3 Tert−/− mice. (B) Scheme of sacrifice and collection of lungs from Tert+/+ and G3 Tert−/− mice at different time points. (C) Representative images showing a Q-FISH for telomere spot fluorescence in ATII and club cells (Cy3Tel probe [red], SFTPC- and SCGB1A1-positive cells [green]) and nuclei stained with DAPI (blue; left and center right), SFTPC (brown, red arrowheads; center left), and SCGB1A1 (brown, green arrowheads; right) immunostainings in lung sections from Tert+/+ and G3 Tert−/− at different time points. (D–I) Quantification of mean telomere fluorescence (mean spot intensity; D and F), percentage of short telomeres in ATII and club cells corresponding to the 20th percentile of the fluorescence intensity values of controls (5-wk-old Tert+/+ mice; E and G), and SFTPC-positive ATII cells (%) and SCGB1A1-positive club cells per epithelium length (millimeters; H and I). Quantifications were performed on five different alveolar areas or bronchi in a random way. Data are expressed as mean ± SEM (n = 4 animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis, and Dunn–Sidak multiple comparison test). ns, not significant.](https://figures.cochat.ai/paper-figures/7291dc599f4d484faf0785adf7b35579/telomerase-treatment-prevents-lung-profibrotic-pathologies-associated-with-figure-1.jpg)



![Figure 5. Physiological aging leads to impaired surfactant activity which is partially restored by telomerase gene therapy in both wild-type mice and telomerase-deficient mice. (A and B) Captive bubble results from Tert+/+ and G3 Tert−/− mice with increasing weeks of age. (C and D) Captive bubble results from 71–72-wk-old Tert+/+ and G3 Tert−/− mice treated with AAV9-empty or AAV9-Tert. (A and C) Top: Surface tension obtained 1 s after applying surfactant onto the air bubble (initial adsorption). Bottom: Surface tension obtained 1 s after the bubble expansion (postexpansion [PE] adsorption). (B and D) Top: Representative γ-relative area isotherms obtained under breathing-like dynamic cycles for each group tested. Bottom: Minimum and maximum γ along with the relative area of compression obtained during the 20th cycle. White bars represent Tert+/+ mice. Gray bars represent G3 Tert−/− mice. Data are expressed as mean ± SEM (n = 5–6 animals per group). *, P < 0.05; **, P < 0.01. Between different ages for each condition: One-way ANOVA with post hoc Dunn–Sidak multiple comparison test. Between different conditions within the same age: following a Shapiro–Wilk normality test, two-sample unpaired t test, or Mann–Whitney test when appropriate. γ, surface tension; max, maximum; min, minimum.](https://figures.cochat.ai/paper-figures/83a7bf0506ee43e09cb6b02a43e86288/telomerase-treatment-prevents-lung-profibrotic-pathologies-associated-with-figure-5.jpg)

![Figure 6. Telomerase gene therapy in the mouse lung results in telomere elongation and increased number of ATII and club cells. (A) Experimental protocol for the administration of AAV9-Tert and AAV9-empty virus. 27–30-wk-old Tert+/+ and G3 Tert−/− mice were administered with 2E12vg of AAV9-Tert and AAV9-empty virus by intravenous tail injection. Animals were sacrificed 21 wk later for lung tissue harvesting. (B) Total lung mRNA levels of Tert normalized to 18S expression in AAV9-empty– and AAV9-Tert–treated animals. (C–H) Quantification of mean telomere fluorescence (mean spot intensity; C and E), percentage of short telomeres in ATII and club cells corresponding to the 20th percentile of the fluorescence intensity values of controls (5-wk-old Tert+/+ mice; D and F), and SFTPC-positive ATII cells (%) and SCGB1A1-positive club cells per epithelium length (millimeters) in AAV9-Tert– and AAV9-empty–treated mice (G and H). (I) Representative images showing a Q-FISH for telomere spot fluorescence in ATII and club cells (Cy3Tel probe [red], SFTPC- and SCGB1A1-positive cells [green], and nuclei stained with DAPI [blue]; left and center right), and SFTPC (brown, red arrowheads; center left) and SCGB1A1 (brown, green arrowheads; right) immunostainings in lung sections from Tert+/+ and G3 Tert−/− mice treated with the AAV9-Tert (upper panels) or AAV9-empty (lower panels) virus. (J–L) Changes in total lung mRNA expression levels of the surfactant markers Sftpa1, Sftpc, and Sftpd normalized to 18S expression. Quantifications were performed on five different alveolar areas or bronchi in a random way. Data are expressed as mean ± SEM (n = 4 animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis, and Dunn–Sidak multiple comparison test). ns, not significant.](https://figures.cochat.ai/paper-figures/cc6fac0ba4b4469c8190b9aaa0069ff7/telomerase-treatment-prevents-lung-profibrotic-pathologies-associated-with-figure-6.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistently, expression of telomerase using adeno-associated vectors (AAVs) in alveolar epithelial type II cells led to TAF reduction, decreased inflammation and improved lung function in telomerase-mutant and wild-type aged mice63,64.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [64]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In various murine liver injury models, stellate cells can acquire senescence markers, including p21, p16, and SA-β-gal, and express certain SASP factors80–83.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Self-citationRaghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400
Shelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“In mammals, telomeric DNA consists of TTAGGG repeats bound by a six-protein complex termed “shelterin” (Liu et al., 2004; de Lange, 2005).”
BackgroundAging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954 · cited 1×
“Previous authors have also suggested a role for senescence in IPF (Selman and Pardo, 2014; Spagnolo et al., 2015; Pardo and Selman, 2017; Campisi, 2013).”
BackgroundA DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108 · cited 1×
“To this end, we performed a full characterization of mouse lungs at different ages (5, 8–9, 42–49, and 92–125 wk of age) in both wild-type and third-generation (G3) telomerase-deficient mice with short telomeres (Blasco et al., 1997) as a control for lung pathologies associated with accelerated telomere shortening (Fi…”
MethodSelf-citationSwitching and Signaling at the Telomere
Blackburn, E. H. (2001) · Cell · doi:10.1016/s0092-8674(01)00492-5 · Cited by 2,107 · cited 1×
“Telomeres are protective structures at the ends of eukaryotic chromosomes that are essential for chromosome stability (Blackburn, 2001).”
Research works printed but not linked: 1
- Pardo, 2017, Fibroblast Senescence and Apoptosis, Ajrcmb, 56, 145
Cited by
Telomere dysfunction in ageing and age-related diseases
Rossiello, F., Jurk, D., Passos, J. F., & d’Adda di Fagagna, F. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00842-x · Cited by 754
Cai, Y., Song, W., Li, J., Jing, Y., Liang, C., Zhang, L., Zhang, X., Zhang, W., Liu, B., An, Y., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2161-3 · Cited by 408
Guidelines for minimal information on cellular senescence experimentation in vivo
Ogrodnik, M., Carlos Acosta, J., Adams, P. D., d’Adda di Fagagna, F., Baker, D. J., Bishop, C. L., Chandra, T., Collado, M., Gil, J., Gorgoulis, V., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.059 · Cited by 376
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
Pardo, A., & Selman, M. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0373ps · Cited by 117
Wang, T., Duan, W., Jia, X., Huang, X., Liu, Y., Meng, F., & Ni, C. (2023) · European Respiratory Journal · doi:10.1183/13993003.01720-2023 · Cited by 123
“Furthermore, a previous study also reported that treatment of both wild-type and telomerase-deficient mice with telomerase gene therapy could prevent the onset of profibrotic lung pathologies [46].”
BackgroundGiacomelli, C., Piccarducci, R., Marchetti, L., Romei, C., & Martini, C. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114812 · Cited by 83
Telomere function and regulation from mouse models to human ageing and disease
Jones-Weinert, C. W., Mainz, L., & Karlseder, J. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00800-5 · Cited by 68
“Telomerase re-expression in several mouse models averts gradual decline in tissue function 213,217,222,225–228 , further suggesting a link between TIF-induced senescence and disease.”
Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis
Ptasinski, V., Stegmayr, J., Belvisi, M. G., Wagner, D. E., & Murray, L. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0476tr · Cited by 65
“Notably, another study found that young Tert mice showed loss of AEC2s and club cells, fibroblast activation, DNA damage, senescence, and apoptosis at levels comparable with changes observed in aged versus young wild-type animals (70).”
BackgroundResultSilva, E. D., Vogel, U. B., Hougaard, K. S., Pérez‐Gil, J., Zuo, Y., & Sørli, J. B. (2021) · Current Research in Toxicology · doi:10.1016/j.crtox.2021.05.005 · Cited by 57
Self-citationKiener, M., Roldán, N., Machahua, C., Sengupta, A., Geiser, T., Guenat, O. T., Funke-Chambour, M., Hobi, N., & Julio, M. K. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.644678 · Cited by 54
“Further, the relevance of ATII cells in the repair process is highlighted by studies in which ATII-targeted damage or cellular intrinsic alterations, rather genetic or due to aging, lead to aberrant tissue remodeling (36, 37).”
BackgroundCellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis
Zhang, Y., & Wang, J. (2023) · Advances in respiratory medicine · doi:10.3390/arm91010005 · Cited by 53
“Telomere shortening impairs stem cell function and tissue regeneration [55].”
BackgroundKLF4 regulates TERT expression in alveolar epithelial cells in pulmonary fibrosis
Wang, H., Xu, H., Lyu, W., Xu, Q., Fan, S., Chen, H., Wang, D., Chen, J., & Dai, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04886-7 · Cited by 50
“Consistent with these studies, the current study confirmed the senescence in AECs in IPF lungs, and also proved that the senescence of AECs plays an important role in the progression of IPF [39].”
ResultTelomere Shortening and Its Association with Cell Dysfunction in Lung Diseases
Ruíz, A., Flores‐González, J., Buendía-Roldán, I., & Chávez‐Galán, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010425 · Cited by 49
Mesenchymal cells in the Lung: Evolving concepts and their role in fibrosis
Ligresti, G., Raslan, A., Hong, J., Caporarello, N., Confalonieri, M., & Huang, S. K. (2023) · Gene · doi:10.1016/j.gene.2022.147142 · Cited by 43
DNA damage response at telomeres boosts the transcription of SARS‐CoV‐2 receptor ACE2 during aging
Sepe, S., Rossiello, F., Cancila, V., Iannelli, F., Matti, V., Cicio, G., Cabrini, M., Marinelli, E., Alabi, B. R., di Lillo, A., et al. (2022) · The EMBO Reports · doi:10.15252/embr.202153658 · Cited by 42
Piñeiro‐Hermida, S., Martínez, P., Bosso, G., Flores, J. M., Saraswati, S., Connor, J. R., Lemaire, R., & Blasco, M. A. (2022) · Nature Communications · doi:10.1038/s41467-022-32771-6 · Cited by 41
Self-citationCellular senescence in liver diseases: From mechanisms to therapies
Ge, T., Shao, Y., Bao, X., Xu, W., & Lu, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110522 · Cited by 38
Telomere length dynamics over 10-years and related outcomes in patients with COPD
Córdoba-Lanús, E., Cazorla-Rivero, S., Bello, M. Á. G., Mayato, D., Gonzalvo, F., Ayra‐Plasencia, J., Celli, B. R., & Casanova, C. (2021) · Respiratory Research · doi:10.1186/s12931-021-01616-z · Cited by 37
“On the other hand, telomerase activation has emerged as a potential treatment directed to cases with short telomeres and physiological aging [42].”
BackgroundAlveolar Organoids in Lung Disease Modeling
Purev, E., Bahmed, K., & Kośmider, B. (2024) · Biomolecules · doi:10.3390/biom14010115 · Cited by 34
“Between 8% and 15% of familial IPF cases relate to mutations in telomerase or telomere-protective proteins [125].”
BackgroundProgress in Respiratory Gene Therapy
McLachlan, G., Alton, E. W. F. W., Boyd, A., Clarke, N. K., Davies, J. C., Gill, D. R., Griesenbach, U., Hickmott, J. W., Hyde, S. C., Miah, K. M., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.172 · Cited by 33
Piñeiro‐Hermida, S., Bosso, G., Sánchez-Vazquez, R., Martínez, P., & Blasco, M. A. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01149-6 · Cited by 30
“Next, tissues were washed 3 × 5min in PBS 1X, fixed in 4% formaldehyde for 5 min, washed 3 × 5min in PBS and dehydrated in a 70%–90%–100% ethanol series (5 min each) [72].”
MethodSelf-citationSensitization of the UPR by loss of PPP1R15A promotes fibrosis and senescence in IPF
Monkley, S. J., Overed-Sayer, C. L., Parfrey, H., Rassl, D. M., Crowther, D. C., Escudero‐Ibarz, L., Davis, N., Carruthers, A. M., Berks, R., Coetzee, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00769-7 · Cited by 28
Insights into the Pathogenesis of Pulmonary Fibrosis from Genetic Diseases
Wang, J. Y., & Young, L. R. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0557tr · Cited by 20
Short and dysfunctional telomeres protect from allergen‐induced airway inflammation
Piñeiro‐Hermida, S., Martínez, P., & Blasco, M. A. (2021) · Aging Cell · doi:10.1111/acel.13352 · Cited by 18
Self-citationYang, Y., Chen, Y., Liu, Y., Ning, Z.-D., Zhang, Z., Zhang, Y., Xu, K., & Zhang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1136761 · Cited by 17
“Telomerase gene therapy treatment in wild-type and telomerase-deficient mice has been demonstrated to prevent the development of pulmonary profibrotic lesions (Liu et al., 2019; Piñeiro-Hermida et al., 2020).”
BackgroundmTert induction in p21-positive cells counteracts capillary rarefaction and pulmonary emphysema
Lipskaia, L., Breau, M., Cayrou, C., Churikov, D., Braud, L., Jacquet, J., Born, E., Fouillade, C., Curras-Alonso, S., Bauwens, S., et al. (2024) · EMBO Reports · doi:10.1038/s44319-023-00041-1 · Cited by 15
“…vectors (AAV) encoding the telomerase reverse transcriptase gene ( mTert ) to assess the therapeutic effect of telomerase ectopic expression either in old mice or in mice with experimentally shortened telomeres (Bernardes de Jesus et al, 2012; Povedano et al, 2018; Piñeiro-Hermida et al, 2020).”
Hallmarks of the ageing lung: 10 years later
Baker, J. R., Beaulieu, D., Avcı, E., Huang, E. L., Eickelberg, O., Meiners, S., Savai, R., Lehmann, M., & Königshoff, M. (2026) · European Respiratory Journal · doi:10.1183/13993003.01272-2025 · Cited by 14
“Similarly, physiological ageing in mice induces lung fibrosis with telomere shortening, while telomerase gene therapy prevents fibrosis in telomere-deficient or bleomycin-injured mice [232, 233].”
Roles of telomeres and telomerase in age‑related renal diseases (Review)
Li, H., Wang, B., Li, D., Li, J., Luo, Y., & Dan, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11735 · Cited by 14
“Piñeiro‐Hermida et al (61) revealed an association between the development of idiopathic pulmonary fibrosis and telomere dysfunction and telomerase mutations.”
BackgroundInfluentialTelomeropathies in Interstitial Lung Disease and Lung Transplant Recipients
Southern, B. D., & Gadre, S. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051496 · Cited by 11
“These investigators went on to show that physiologic aging leads to short telomeres and fibrosis in the lung of mice, and that administration of their AAV gene therapy prevented the onset of fibrosis [67].”
Martínez, P., Sánchez-Vazquez, R., Saha, A., Rodríguez-Duque, M. S., Naranjo-Gonzalo, S., Osorio-Chávez, J. S., Villar, A. V., & Blasco, M. A. (2023) · Aging · doi:10.18632/aging.204755 · Cited by 11
Self-citationEarly differential responses elicited by BRAFV600E in adult mouse models
Bosso, G., Lanuza-Gracia, P., Piñeiro‐Hermida, S., Yılmaz, M., Serrano, R., & Blasco, M. A. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04597-z · Cited by 11
“Immuno-FISH Immuno-FISH was performed in formalin-fixed paraffin-embedded mouse lung sections to identify telomeric induced foci (TIF) as previously described [60, 61].”
MethodSelf-citationLiu, J., Yi, Z., Chen, T., Ying, Y., & Hu, Y. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.113226 · Cited by 9
“Utilizing an adeno-associated virus serotype 9 (AAV9)-Tert vector for gene therapy, reactivation of telomerase in the lung can delay disease progression in murine models of pulmonary fibrosis [99].”
Cai, Q., Ma, J., Wang, J., Wang, J., Cui, J., Wu, S., Wang, Z., Wang, N., Wang, J., Yang, D., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.008 · Cited by 8
“40 These studies infer that therapeutic gene delivery using viral vectors may be an effective treatment for pulmonary fi-brosis, including silicosis.”
Šelb, J., Osolnik, K., Kern, I., Korošec, P., & Rijavec, M. (2022) · Cells · doi:10.3390/cells11030372 · Cited by 7
“Furthermore, in mouse models, telomere elongation (through activation of the telomerase enzyme) was shown to prevent the onset of lung profibrotic pathologies [5].”
BackgroundLuo, W., Gu, Y., Fu, S., Wang, J., Zhang, J., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115762 · Cited by 7
Elliot, S. J., Anderson-Bell, D., Roos, B. B., Rubio, G. A., Xia, X., Pereira‐Simon, S., Catanuto, P., Civettini, G., Hagen, E. S., Arvanitis, C., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102461 · Cited by 6
“82 BLM reduces telomerase activity and, accordingly, telomere length in epithelial tissues.”
Fueling the fire: metabolic dysfunction and senescence as drivers of lung aging and disease
Kliment, C. R., Gurkar, A. U., Cárdenes, N., Ramonell, R. P., Finkel, T., & Königshoff, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00024.2025 · Cited by 7
Saad, F. A. (2024) · Current Gene Therapy · doi:10.2174/0115665232286489240320051925 · Cited by 6
Dong, Z., Wang, X., Wang, P., Bai, M., Wang, T., Chu, Y., & Qin, Y. (2024) · Advanced Biology · doi:10.1002/adbi.202400297 · Cited by 6
Fan, Q., Yu, S., Sun, X. S., Dong, Y., Chen, Y., & Jia, L. (2025) · Psychology Research and Behavior Management · doi:10.2147/prbm.s533200 · Cited by 5
Unlocking Alveolar Regeneration: AT2 Stem Cells, Signaling Networks, and Therapeutic Frontiers
Zhang, Y., Zhou, Y., Wang, J., & Wang, Q. (2026) · Stem Cell Reviews and Reports · doi:10.1007/s12015-026-11086-9 · Cited by 4
“TERT/TERC mutations induce telomerase dysfunction, telomere shortening, and impaired stem cell function with compromised tissue regeneration [ 3, 104]. of lung adenocarcinoma and adverse prognosis, rendering it a valuable diagnostic and prognostic biomarker [ 132].”
Tlatelpa-Romero, B., Cisneros, L. G. V.-D.-L., Cañadas, O., Blanco-Rivero, A., Olmeda, B., Pérez‐Gil, J., Mendoza-Milla, C., Martinez-Vaquero, J. L., Romero, Y., Contreras‐Cruz, D. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157132 · Cited by 3
“Surfactant dysfunction may precede fibrosis and serve as an early marker [34].”
Self-citationInvestigational gene expression inhibitors for the treatment of idiopathic pulmonary fibrosis
Spagnolo, P., Tonelli, R., Mura, M., Reisman, W. M., Sotiropoulou, V., & Tzouvelekis, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2462592 · Cited by 3
“To this end, efforts focusing on telomerase gene therapy and its potential to delay or prevent the development of lung fibrosis are of particular interest [248].”
Telomerase Prevents Emphysema in Old Mice by Sustaining Subpopulations of Endothelial and AT2 CellsPreprint
Breau, M., Cayrou, C., Churikov, D., Fouillade, C., Curras-Alonso, S., Bauwens, S., Jourquin, F., Braud, L., FIORE, F., Castellano, R., et al. (2021) · Research Square · doi:10.1101/2021.01.07.425708 · Cited by 3
Mendelian causes of early-onset emphysema: a review of the current literature
Karabatic, A., van den Berge, M., Carroll, T. P., Guryev, V., & Faiz, A. (2025) · European Respiratory Review · doi:10.1183/16000617.0125-2025 · Cited by 2
“For telomere shortening, adeno-associated virus (AAV) – telomerase reverse transcriptase (TERT) gene therapy in mice has been shown to decelerate telomere shortening, which in turn decreases lung exacerbations [79].”
The crucial role of normative ageing in respiratory pathogenesis
Weight, C. M., Tatler, A. L., Huckstepp, R. T. R., Adcock, I. M., Barnes, P. J., van Beek, E. J. R., Christopher, G., Clifford, R. L., Dhasmana, D., Hart, S. P., et al. (2026) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2026.100842 · Cited by 2
The telomeric DNA damage response as a therapeutic target in idiopathic pulmonary fibrosis
Rossiello, F., Cicio, G., Sepe, S., Mancheno-Ferris, A., Cancila, V., Castellini, A., Rey, F., Bertolazzi, G., Oppezzo, A., Marinelli, E., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00500-x · Cited by 3
“Similar to IPF patients, mice with genetic inactivation of telomerase components and short telomeres show tDDR activation, in fl ammation, and fi brosis in the lungs (Chen et al, 2015; Piñeiro-Hermida et al, 2020).”
InfluentialInduction of telomerase in p21-positive cells counteracts capillaries rarefaction in aging mice lungPreprint
Lipskaia, L., Breau, M., Cayrou, C., Churikov, D., Braud, L., Fouillade, C., Curras-Alonso, S., Bauwens, S., Jourquin, F., FIORE, F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.27.514005 · Cited by 2
Sánchez-Vazquez, R., García-Oteyza, S. B., Serrano, R., Flores, J. M., Martínez, P., & Blasco, M. A. (2025) · Genes & Development · doi:10.1101/gad.352855.125 · Cited by 2
“Atrophies of the intestinal epithelia, lung profibrotic pathologies, and defective spermatogenesis are frequent and life-threatening degenerative lesions associated with short telomeres in telomerase-deficient mice (Lee et al. 1998; Herrera et al. 1999; Piñeiro-Hermida et al. 2020).”
Self-citationTelomere Shortening in Interstitial Lung Disease: Challenges and Promises
Jin, H., Song, J., Gao, R., Sha, B., Wang, S., Luo, P., Yu, L., Xu, X., & Wang, X. (2025) · The Clinical Respiratory Journal · doi:10.1111/crj.70103 · Cited by 1
“AAV-Tert gene therapy also reduced lung fibroblasts in aged wild-type mice and Ter-knockout mice; slowed down telomere damage, senescence, and apoptosis in the lungs of both groups of mice; and significantly improved surface active substance damage in the lungs of both groups of mice [47].”
Zhong, G., Wan, N., Wang, S., Xie, W., Zhang, C., Ding, X., Li, Y., Zhang, Y., & Dai, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1811649 · Cited by 1
Marión, R. M., González, J. C., Flores, J. M., Piñeiro-Yáñez, E., Serrano, R., & Blasco, M. A. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117786 · Cited by 2
Self-citationThe ongoing quest for a fountain of youth: Cell therapy for pulmonary fibrosis
Chambers, D. C. (2020) · Respirology · doi:10.1111/resp.13938
El envejecimiento: ¿Podemos frenarlo? Telómeros/Telomerasa, Senescencia Celular Primera Parte
Prof. Jubilado, U. C. D. V., & Garrido, M. D. R. (2023) · Revista de la Facultad de Farmacia · doi:10.54305/rffucv.2023.86.3.15
Gomes, W. R. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2024.tde-25072024-153611
THE ROLE OF TELOMERASE IN CELULLAR SENESCENCE AND ITS IMPLICATIONS FOR ANTI-AGING THERAPY
Defi, R. S., Ernestia, H., & Pukan, F. K. (2025) · Biofaal Journal · doi:10.30598/biofaal.v6i1pp20-28
İdiyopatik Pulmoner Fibrozis Tanıdan Tedaviye Güncel Yaklaşım
Ölmez, H. (2025) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3774
Córdoba-Lanús, E., Cazorla-Rivero, S., García-Bello, M. A., Mayato, D., Gonzalvo, F. R., Ayra-Plasencia, J., Celli, B. R., & Casanova, C. (2021) · Figshare · doi:10.6084/m9.figshare.14068059
Innovative Treatment in Aplastic Anemia and Other Inherited Bone Marrow Failure Syndromes
Mishra, K., & Kapoor, R. (2026) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-026-02462-z
Zhan, H., Zheng, R., Li, Y., Liu, X. W., Shi, Y., Chen, R., Hou, Q., Huang, H. F., & Lin, M. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.034
“Treatment with AAV9-TERT could also potentially reduce lung DNA damage, delay senescence, and lower susceptibility to non-malignant pulmonary diseases 195,196 .”
Qian, Z., Chen, Y., Qian, C., & Guo, Q. (2026) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2026.106372
Applegate, L. A., Porcello, A., & Laurent, A. E. (2026) · Biomedicines · doi:10.3390/biomedicines14091888
“…fibroproliferative phase, subsequent studies must employ repetitive bleomycin dosing regimens or aging transgenic murine models (e.g., telomerase-deficient mice) that genuinely mimic the progressive, non-resolving pathological environment of end-stage human interstitial lung disease [6,45,113].”
Metadata
- Authors
- Piñeiro-Hermida, S., Autilio, C., Martínez, P., Bosch, F., Pérez-Gil, J., & Blasco, M. A.
- Affiliations
- Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre, Madrid, Spain 1
- Universidad Complutense de Madrid (ES)
- Spanish National Cancer Research Centre (ES)
- Universitat Autònoma de Barcelona (ES)
- Department of Biochemistry and Molecular Biology, Research Institute “Hospital 12 de Octubre (imas12),” Complutense University, Madrid, Spain 2
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2020-08-10
- Volume
- 219
- Issue
- 10
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC7659728
- OpenAlex
- W3048397235
- Cited by
- 60
- References
- 99
- Citations by year
- 2026: 10 · 2025: 9 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 12 · 2020: 3
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Cell Biology (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Library Open Repository (Universidad Complutense Madrid) (submittedVersion, cc-by-nc-sa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- RIUR (Universidad de La Rioja) (submittedVersion, other-oa)
- Funders
- Spanish Ministry of Economy and Competitiveness (SAF2013-45111-R, SAF2015-72455-EXP)
- Comunidad de Madrid Project (S2017/BMD-3770)
- World Cancer Research Fund (16-1177)
- Spanish Ministry of Science and Innovation (RTI2018-094564-B-100, DTS17/ 00152, SAF2017-82623-R)
- Regional Government of Madrid (P2018/NMT-4389)
- Fundación Botín
- Fundación Banco Santander
- Instituto de Salud Carlos III
- European Regional Development Fund
- Spanish Estate Research Agency
- RyPSE-CM (B2017/BMD-3770)
- Community of Madrid
- European Social Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- telomerase, idiopathic pulmonary fibrosis, physiological aging, telomere shortening, pulmonary fibrosis, cellular senescence, alveolar type II cells, Clara cells, fibroblast activation, collagen deposition, DNA damage
- MeSH terms
- Aging, Animals, Bleomycin, Disease Models, Animal, DNA Damage, Humans, Lung, Telomere, Cellular Senescence, Mice, Knockout, Telomerase, Mice, Idiopathic Pulmonary Fibrosis, Telomere Shortening
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.